Literature DB >> 9952038

Effects of continuous oral nicotine administration on brain nicotinic receptors and responsiveness to nicotine in C57Bl/6 mice.

J A Sparks1, J R Pauly.   

Abstract

The route of drug delivery is an important consideration in studies that evaluate the long-term bio-behavioral adaptations that occur in response to chronic drug administration. Continuous infusions (intravenous or subcutaneous) or intermittent intraperitoneal (or subcutaneous) injections are the most commonly utilized routes of chronic drug delivery in these studies. The purpose of the present study was to determine the effects of chronic oral nicotine exposure on sensitivity to nicotine and brain nicotinic cholinergic receptors in female C57Bl/6 mice. Mice were randomized to different treatment groups that received 2% saccharin, containing 0-200 microg/ml nicotine (free base). In preliminary experiments, radiotelemetry devices were implanted in the mice; consumption of the nicotine-containing drinking solution caused a significant increase in home-cage nocturnal (but not diurnal) activity and also altered circadian alterations in body temperature. Oral nicotine exposure resulted in dose-related elevations in plasma levels of cotinine, a primary nicotine metabolite. Continuous exposure (30 days) to oral nicotine (200 microg/ml) resulted in the expression of significant tolerance to the locomotor depressant and hypothermic actions of acute nicotine challenge. This tolerance was accompanied by a significant increase in brain nicotinic receptor number assessed by quantitative auto-radiography using [3H]-cytisine (alpha4 nAChr) and [125I]-alpha-bungarotoxin (alpha7 nAChr) as radioligands. These results suggest that chronic oral nicotine delivery to female C57Bl/6 mice results in behavioral and biochemical changes that resemble changes that occur following other routes of chronic nicotine delivery.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9952038     DOI: 10.1007/s002130050818

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  71 in total

1.  Regulation of the distribution and function of [(125)I]epibatidine binding sites by chronic nicotine in mouse embryonic neuronal cultures.

Authors:  Cristian A Zambrano; Rakel M Salamander; Allan C Collins; Sharon R Grady; Michael J Marks
Journal:  J Pharmacol Exp Ther       Date:  2012-04-24       Impact factor: 4.030

2.  Spectral confocal imaging of fluorescently tagged nicotinic receptors in knock-in mice with chronic nicotine administration.

Authors:  Anthony Renda; Raad Nashmi
Journal:  J Vis Exp       Date:  2012-02-10       Impact factor: 1.355

3.  Traumatic brain injury elicits similar alterations in α7 nicotinic receptor density in two different experimental models.

Authors:  Peter-Georg Hoffmeister; Cornelius K Donat; Martin U Schuhmann; Cornelia Voigt; Bernd Walter; Karen Nieber; Jürgen Meixensberger; Reinhard Bauer; Peter Brust
Journal:  Neuromolecular Med       Date:  2010-09-21       Impact factor: 3.843

Review 4.  Mouse models for studying genetic influences on factors determining smoking cessation success in humans.

Authors:  F Scott Hall; Athina Markou; Edward D Levin; George R Uhl
Journal:  Ann N Y Acad Sci       Date:  2012-02       Impact factor: 5.691

5.  The effects of lobeline on nicotine withdrawal-induced depression-like behavior in mice.

Authors:  Monzurul Amin Roni; Shafiqur Rahman
Journal:  Psychopharmacology (Berl)       Date:  2014-02-28       Impact factor: 4.530

6.  An autoradiographic analysis of rat brain nicotinic receptor plasticity following dietary choline modification.

Authors:  M V Guseva; D M Hopkins; J R Pauly
Journal:  Pharmacol Biochem Behav       Date:  2006-06-06       Impact factor: 3.533

7.  Perinatal exposure to nicotine causes deficits associated with a loss of nicotinic receptor function.

Authors:  Gary Cohen; Jean-Christophe Roux; Régis Grailhe; Girvan Malcolm; Jean-Pierre Changeux; Hugo Lagercrantz
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-28       Impact factor: 11.205

8.  Placebo-controlled pilot trial of mecamylamine for treatment of autism spectrum disorders.

Authors:  L Eugene Arnold; Michael G Aman; Jill Hollway; Elizabeth Hurt; Bethany Bates; Xiaobai Li; Cristan Farmer; Rene Anand; Susan Thompson; Yaser Ramadan; Craig Williams
Journal:  J Child Adolesc Psychopharmacol       Date:  2012-04-26       Impact factor: 2.576

9.  Transgenerational transmission of hyperactivity in a mouse model of ADHD.

Authors:  Jinmin Zhu; Kevin P Lee; Thomas J Spencer; Joseph Biederman; Pradeep G Bhide
Journal:  J Neurosci       Date:  2014-02-19       Impact factor: 6.167

10.  Dietary choline supplementation improves behavioral, histological, and neurochemical outcomes in a rat model of traumatic brain injury.

Authors:  Maria V Guseva; Deann M Hopkins; Stephen W Scheff; James R Pauly
Journal:  J Neurotrauma       Date:  2008-08       Impact factor: 5.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.